Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DZ2B3I
|
|||
| Drug Name |
Pegozafermin
|
|||
| Synonyms |
BIO89-100
Click to Show/Hide
|
|||
| Indication | Hypertriglyceridemia [ICD-11: 5C80.1; ICD-10: E78.1, E78.3; ICD-9: 272.1, 427] | Phase 3 | [1] | |
| Company |
89bio
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Fibroblast growth factor-21 (FGF21) | Target Info | Agonist | [2] |
| KEGG Pathway | MAPK signaling pathway | |||
| Ras signaling pathway | ||||
| Rap1 signaling pathway | ||||
| PI3K-Akt signaling pathway | ||||
| Regulation of actin cytoskeleton | ||||
| Pathways in cancer | ||||
| Melanoma | ||||
| Reactome | Facilitative Na+-independent glucose transporters | |||
| Glucose transport | ||||
| WikiPathways | Regulation of Actin Cytoskeleton | |||
| Aryl Hydrocarbon Receptor | ||||
| SREBP signalling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05852431) A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia (SHTG): The ENTRUST Study. U.S.National Institutes of Health. | |||
| REF 2 | Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study. Lancet Gastroenterol Hepatol. 2023 Feb;8(2):120-132. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.